Stock Track | West Pharmaceutical Plunges 20% in Pre-Market as 2025 Outlook Misses Estimates on Destocking, Strong Dollar

Stock Track

Feb 13, 2025

West Pharmaceutical Services Inc. (WST) stock plummeted around 20% in Thursday's pre-market session after the medical equipment maker's profit and revenue outlook for 2025 fell well short of Wall Street expectations.

The company forecast 2025 adjusted earnings per share of $6 to $6.20, compared to the average analyst estimate of $7.44 according to LSEG data. It also projected full-year revenue of $2.88 billion to $2.91 billion, below the consensus estimate of $3.04 billion.

West Pharma cited two key factors weighing on its guidance - biotech customers reducing inventory levels built up during pandemic-era supply chain disruptions, and headwinds from a strong U.S. dollar impacting overseas revenues. CEO Eric Green said the "impact of destocking continues to moderate" but is still an overhang.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1177099400"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177099400\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177099400?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177099400","market":"us","top_or_hot":-1,"title":"Stock Track | West Pharmaceutical Plunges 20% in Pre-Market as 2025 Outlook Misses Estimates on Destocking, Strong Dollar","media":"Stock Track","content":"<p>West Pharmaceutical Services Inc. (WST) stock plummeted around 20% in Thursday's pre-market session after the medical equipment maker's profit and revenue outlook for 2025 fell well short of Wall Street expectations.</p>\n\n<p>The company forecast 2025 adjusted earnings per share of $6 to $6.20, compared to the average analyst estimate of $7.44 according to LSEG data. It also projected full-year revenue of $2.88 billion to $2.91 billion, below the consensus estimate of $3.04 billion.</p>\n\n<p>West Pharma cited two key factors weighing on its guidance - biotech customers reducing inventory levels built up during pandemic-era supply chain disruptions, and headwinds from a strong U.S. dollar impacting overseas revenues. CEO Eric Green said the \"impact of destocking continues to moderate\" but is still an overhang.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | West Pharmaceutical Plunges 20% in Pre-Market as 2025 Outlook Misses Estimates on Destocking, Strong Dollar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | West Pharmaceutical Plunges 20% in Pre-Market as 2025 Outlook Misses Estimates on Destocking, Strong Dollar\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>West Pharmaceutical Services Inc. (WST) stock plummeted around 20% in Thursday's pre-market session after the medical equipment maker's profit and revenue outlook for 2025 fell well short of Wall Street expectations.</p>\n\n<p>The company forecast 2025 adjusted earnings per share of $6 to $6.20, compared to the average analyst estimate of $7.44 according to LSEG data. It also projected full-year revenue of $2.88 billion to $2.91 billion, below the consensus estimate of $3.04 billion.</p>\n\n<p>West Pharma cited two key factors weighing on its guidance - biotech customers reducing inventory levels built up during pandemic-era supply chain disruptions, and headwinds from a strong U.S. dollar impacting overseas revenues. CEO Eric Green said the \"impact of destocking continues to moderate\" but is still an overhang.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WST","symbol_name":"West Pharmaceutical Services Inc","start_time":0,"source_url":"","article_id":"1177099400","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177099400","pubTimestamp":1739456429,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"West Pharmaceutical Services Inc.  stock plummeted around 20% in Thursday's pre-market session after the medical equipment maker's profit and revenue outlook for 2025 fell well short of Wall Street expectations.The company forecast 2025 adjusted earnings per share of $6 to $6.20, compared to the average analyst estimate of $7.44 according to LSEG data. It also projected full-year revenue of $2.88 billion to $2.91 billion, below the consensus estimate of $3.04 billion.West Pharma cited two key fa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WST":"West Pharmaceutical Services Inc"},"translate_title":"由于2025年展望未达去库存和美元走强的预期，West Pharmaceutical盘前暴跌20%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WST":1},"content_text":"West Pharmaceutical Services Inc. (WST) stock plummeted around 20% in Thursday's pre-market session after the medical equipment maker's profit and revenue outlook for 2025 fell well short of Wall Street expectations.\nThe company forecast 2025 adjusted earnings per share of $6 to $6.20, compared to the average analyst estimate of $7.44 according to LSEG data. It also projected full-year revenue of $2.88 billion to $2.91 billion, below the consensus estimate of $3.04 billion.\nWest Pharma cited two key factors weighing on its guidance - biotech customers reducing inventory levels built up during pandemic-era supply chain disruptions, and headwinds from a strong U.S. dollar impacting overseas revenues. CEO Eric Green said the \"impact of destocking continues to moderate\" but is still an overhang.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}